His primary scientific interests are in Antibody, Immunology, Molecular biology, Monoclonal antibody and Receptor. The Antibody study combines topics in areas such as In vivo, Recombinant DNA, Antigen and Virology. His Immunology research is multidisciplinary, relying on both Cytotoxic T cell and Cancer research.
His Molecular biology research includes elements of Transgene, Tyrosine kinase, Syk, Complement system and Antibody-dependent cell-mediated cytotoxicity. His Monoclonal antibody research incorporates themes from Cancer biology and Cancer therapy. His Receptor research includes themes of Alpha, Immune complex, Phagocytosis and Arthus reaction.
Jan G. J. van de Winkel mainly focuses on Antibody, Immunology, Receptor, Molecular biology and Monoclonal antibody. His studies deal with areas such as Cancer research, Antigen and Virology as well as Antibody. His Cancer research study integrates concerns from other disciplines, such as Cancer and Epidermal growth factor receptor.
His Immunology study combines topics from a wide range of disciplines, such as In vivo and Microbiology. His Receptor research integrates issues from Signal transduction and Cell biology. His research in Molecular biology intersects with topics in Genetically modified mouse, Transgene, Recombinant DNA, Immunoglobulin G and Epitope.
Jan G. J. van de Winkel mainly investigates Antibody, Molecular biology, Immunology, Cancer research and Antibody-dependent cell-mediated cytotoxicity. His Antibody research is multidisciplinary, incorporating perspectives in Antigen and Virology. His work deals with themes such as Recombinant DNA, Immunoglobulin G, Immune system and Immunoglobulin E, Galactose α 1 3 galactose, which intersect with Molecular biology.
CD20, Immunotherapy, Fc receptor, Daratumumab and Immunoglobulin A are the core of his Immunology study. His Cancer research study incorporates themes from Cytotoxic T cell and Growth factor receptor. The concepts of his Antibody-dependent cell-mediated cytotoxicity study are interwoven with issues in Epidermal growth factor receptor and Effector.
The scientist’s investigation covers issues in Antibody, Immunology, Molecular biology, Immunotherapy and Cytotoxic T cell. Jan G. J. van de Winkel regularly ties together related areas like Dissociation constant in his Antibody studies. The various areas that Jan G. J. van de Winkel examines in his Immunology study include Signal transduction and Binding site.
His research investigates the connection with Molecular biology and areas like Immunoglobulin G which intersect with concerns in Innate immune system, Cell killing, Complement component 5a and Complement system. Jan G. J. van de Winkel has included themes like IgG binding, Receptor, Immune complex and Bispecific Antibody MDX-H210 in his Immunotherapy study. His Cytotoxic T cell study combines topics in areas such as Stromal cell, Complement-dependent cytotoxicity and SLAMF7, Isatuximab, Daratumumab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.
Jan G.J. van de Winkel;Peter J.A. Capel.
Immunology Today (1993)
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
Marijn van der Neut Kolfschoten;Janine Schuurman;Mario Losen;Wim K. Bleeker.
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel.
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker.
Journal of Immunology (2011)
Impaired IgG-Dependent Anaphylaxis and Arthus Reaction in FcγRIII (CD16) Deficient Mice
Wouter L.W Hazenbos;J.Engelbert Gessner;Frans M.A Hofhuis;Henri Kuipers.
Complement is activated by IgG hexamers assembled at the cell surface.
Christoph A. Diebolder;Frank J. Beurskens;Rob N. de Jong;Roman I. Koning.
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility.
Chieko Kyogoku;Hilde M. Dijstelbloem;Naoyuki Tsuchiya;Yoko Hatta.
Arthritis & Rheumatism (2002)
Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies
Yashwant M. Deo;Robert F. Graziano;Roland Repp;Jan G.J. van de Winkel.
Immunology Today (1997)
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Aran F Labrijn;Antonio Ortiz Buijsse;Ewald T J van den Bremer;Annemiek Y W Verwilligen.
Nature Biotechnology (2009)
Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1
Marjan Hezareh;Ann J. Hessell;Richard C. Jensen;Jan G. J. van de Winkel.
Journal of Virology (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: